The epidemiology of dengue outbreaks in 2016 and 2017 in Ouagadougou, Burkina Faso.

Burkina Faso Dengue Epidemiology Infectious disease Outbreak Public health Serotypes Viral disease Viruses

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 13 06 2019
revised: 27 10 2019
accepted: 30 06 2020
entrez: 23 7 2020
pubmed: 23 7 2020
medline: 23 7 2020
Statut: epublish

Résumé

Dengue is prevalent in as many as 128 countries with more than 100 million clinical episodes reported annually and four billion people estimated to be at risk. While dengue fever is systematically diagnosed in large parts of Asia and South America, the disease burden in Africa is less well investigated. This report describes two consecutive dengue outbreaks in Ouagadougou, Burkina Faso in 2016 and 2017. Blood samples of febrile patients received at Schiphra laboratory in Ouagadougou, Burkina Faso, were screened for dengue infection using SD Bioline Dengue Duo rapid diagnostic test kits (Standard Diagnostics, Suwon, Republic of Korea). A total of 1,397 and 1,882 cases were reported by a single laboratory in 2016 and 2017, respectively. Most cases were at least 15 years of age and the results corroborated reports from WHO indicating the circulation of three dengue virus serotypes in Burkina Faso. This study complements data from other, simultaneously conducted surveillance efforts, and indicates that the dengue disease burden might be underestimated in sub-Saharan African nations. Dengue surveillance should be enhanced in African settings to determine the burden more accurately, and accelerated efforts towards a dengue vaccine should be put in place.

Sections du résumé

BACKGROUND BACKGROUND
Dengue is prevalent in as many as 128 countries with more than 100 million clinical episodes reported annually and four billion people estimated to be at risk. While dengue fever is systematically diagnosed in large parts of Asia and South America, the disease burden in Africa is less well investigated. This report describes two consecutive dengue outbreaks in Ouagadougou, Burkina Faso in 2016 and 2017.
METHODS METHODS
Blood samples of febrile patients received at Schiphra laboratory in Ouagadougou, Burkina Faso, were screened for dengue infection using SD Bioline Dengue Duo rapid diagnostic test kits (Standard Diagnostics, Suwon, Republic of Korea).
RESULTS RESULTS
A total of 1,397 and 1,882 cases were reported by a single laboratory in 2016 and 2017, respectively. Most cases were at least 15 years of age and the results corroborated reports from WHO indicating the circulation of three dengue virus serotypes in Burkina Faso.
CONCLUSION CONCLUSIONS
This study complements data from other, simultaneously conducted surveillance efforts, and indicates that the dengue disease burden might be underestimated in sub-Saharan African nations. Dengue surveillance should be enhanced in African settings to determine the burden more accurately, and accelerated efforts towards a dengue vaccine should be put in place.

Identifiants

pubmed: 32695907
doi: 10.1016/j.heliyon.2020.e04389
pii: S2405-8440(20)31233-0
pii: e04389
pmc: PMC7364030
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e04389

Informations de copyright

© 2020 The Authors.

Références

PLoS One. 2014 Mar 19;9(3):e90037
pubmed: 24646519
PLoS One. 2019 Mar 6;14(3):e0213301
pubmed: 30840708
Emerg Infect Dis. 2011 Aug;17(8):1349-54
pubmed: 21801609
Nature. 2013 Apr 25;496(7446):504-7
pubmed: 23563266
PLoS Negl Trop Dis. 2012;6(8):e1760
pubmed: 22880140
Rev Med Virol. 2016 May;26(3):183-96
pubmed: 26922851
Am J Trop Med Hyg. 2009 Oct;81(4):645-50
pubmed: 19815880
PLoS Negl Trop Dis. 2019 Dec 6;13(12):e0007882
pubmed: 31809504
Lancet Infect Dis. 2016 Jun;16(6):712-723
pubmed: 26874619
Paediatr Int Child Health. 2012 May;32 Suppl 1:18-21
pubmed: 22668445
Sci Data. 2014 May 27;1:140004
pubmed: 25977762
Am J Trop Med Hyg. 2000 Mar;62(3):378-83
pubmed: 11037781

Auteurs

Justin Im (J)

International Vaccine Institute, Seoul, Republic of Korea.

Ruchita Balasubramanian (R)

International Vaccine Institute, Seoul, Republic of Korea.
Princeton University, Princeton, NJ, USA.

Moussa Ouedraogo (M)

Laboratorie d'Analyses Medicales, Centre Médical avec Antenne chirurgicale Protestant Schiphra, Ouagadougou, Burkina Faso.

Lady Rosny Wandji Nana (LR)

Institut Supérieur des Sciences de la Population, Université de Ouagadougou, Ouagadougou, Burkina Faso.

Ondari D Mogeni (OD)

International Vaccine Institute, Seoul, Republic of Korea.

Hyon Jin Jeon (HJ)

International Vaccine Institute, Seoul, Republic of Korea.
The Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

Tayma van Pomeren (T)

International Vaccine Institute, Seoul, Republic of Korea.
Institut Supérieur des Sciences de la Population, Université de Ouagadougou, Ouagadougou, Burkina Faso.

Andrea Haselbeck (A)

International Vaccine Institute, Seoul, Republic of Korea.

Jacqueline Kyungah Lim (JK)

International Vaccine Institute, Seoul, Republic of Korea.

Kristi Prifti (K)

International Vaccine Institute, Seoul, Republic of Korea.

Stephen Baker (S)

The Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

Christian G Meyer (CG)

Duy Tan University, Da Nang, Viet Nam.
Institute for Tropical Medicine, Eberhard Karls University, Tübingen, Germany.

Jerome H Kim (JH)

International Vaccine Institute, Seoul, Republic of Korea.

John D Clemens (JD)

International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh.
University of California, Fielding School of Public Health, Los Angeles, USA.

Florian Marks (F)

International Vaccine Institute, Seoul, Republic of Korea.
The Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

Abdramane Bassiahi Soura (AB)

Institut Supérieur des Sciences de la Population, Université de Ouagadougou, Ouagadougou, Burkina Faso.

Classifications MeSH